358 related articles for article (PubMed ID: 32601079)
21. Single and combination immunotherapy with chemotherapy and the risk of AKI in patients with solid cancer.
de Brito GA; Junior APN; Silva MBE; Bettim BB; Pereira BJ
Clin Exp Nephrol; 2024 Apr; 28(4):273-281. PubMed ID: 37995062
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
Cortazar FB; Marrone KA; Troxell ML; Ralto KM; Hoenig MP; Brahmer JR; Le DT; Lipson EJ; Glezerman IG; Wolchok J; Cornell LD; Feldman P; Stokes MB; Zapata SA; Hodi FS; Ott PA; Yamashita M; Leaf DE
Kidney Int; 2016 Sep; 90(3):638-47. PubMed ID: 27282937
[TBL] [Abstract][Full Text] [Related]
23. Acute Kidney Injury After Abdominal Surgery: Incidence, Risk Factors, and Outcome.
Long TE; Helgason D; Helgadottir S; Palsson R; Gudbjartsson T; Sigurdsson GH; Indridason OS; Sigurdsson MI
Anesth Analg; 2016 Jun; 122(6):1912-20. PubMed ID: 27195635
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcomes of acute kidney injury developing outside the hospital in elderly.
Turgutalp K; Bardak S; Horoz M; Helvacı I; Demir S; Kiykim AA
Int Urol Nephrol; 2017 Jan; 49(1):113-121. PubMed ID: 27704319
[TBL] [Abstract][Full Text] [Related]
25. Mortality after acute kidney injury and acute interstitial nephritis in patients prescribed immune checkpoint inhibitor therapy.
Baker ML; Yamamoto Y; Perazella MA; Dizman N; Shirali AC; Hafez N; Weinstein J; Simonov M; Testani JM; Kluger HM; Cantley LG; Parikh CR; Wilson FP; Moledina DG
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35354588
[TBL] [Abstract][Full Text] [Related]
26. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Renal Toxicity: Illustrative Case and Review.
Sise ME; Seethapathy H; Reynolds KL
Oncologist; 2019 Jun; 24(6):735-742. PubMed ID: 30902916
[TBL] [Abstract][Full Text] [Related]
27. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
[TBL] [Abstract][Full Text] [Related]
28. Combination therapy with immune check point inhibitors and acute kidney injury.
Valentin A; Møller AKH; Palshof JA; Broberg B; Gravesen E; Svane IM; Hansen D
Acta Oncol; 2023 Feb; 62(2):121-125. PubMed ID: 36755491
[TBL] [Abstract][Full Text] [Related]
29. Incidence and risk factors for acute kidney injury in head and neck cancer patients treated with concurrent chemoradiation with high-dose cisplatin.
van der Vorst MJDL; Neefjes ECW; Toffoli EC; Oosterling-Jansen JEW; Vergeer MR; Leemans CR; Kooistra MP; Voortman J; Verheul HMW
BMC Cancer; 2019 Nov; 19(1):1066. PubMed ID: 31703649
[TBL] [Abstract][Full Text] [Related]
30. Incidence, risk factors and prognosis of acute kidney injury in patients treated with immune checkpoint inhibitors: a retrospective study.
Ji MS; Wu R; Feng Z; Wang YD; Wang Y; Zhang L; Sun XF; Chen XM; He KL; Cai GY
Sci Rep; 2022 Nov; 12(1):18752. PubMed ID: 36335144
[TBL] [Abstract][Full Text] [Related]
31. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis.
Manohar S; Kompotiatis P; Thongprayoon C; Cheungpasitporn W; Herrmann J; Herrmann SM
Nephrol Dial Transplant; 2019 Jan; 34(1):108-117. PubMed ID: 29762725
[TBL] [Abstract][Full Text] [Related]
32. Association of Anti-Programmed Cell Death 1 Antibody Treatment With Risk of Recurrence of Toxic Effects After Immune-Related Adverse Events of Ipilimumab in Patients With Metastatic Melanoma.
Brunot A; Grob JJ; Jeudy G; Grange F; Guillot B; Kramkimel N; Mortier L; Le Corre Y; Aubin FF; Mansard S; Lebbé C; Blom A; Montaudie H; Giacchero D; Prey S; Legoupil D; Guyot A; Amini-Adle M; Granel-Brocard F; Meyer N; Dinulescu M; Edeline J; Campillo-Gimenez B; Lesimple T
JAMA Dermatol; 2020 Sep; 156(9):982-986. PubMed ID: 32667663
[TBL] [Abstract][Full Text] [Related]
33. Renal effects of immune checkpoint inhibitors.
Izzedine H; Mateus C; Boutros C; Robert C; Rouvier P; Amoura Z; Mathian A
Nephrol Dial Transplant; 2017 Jun; 32(6):936-942. PubMed ID: 28025384
[TBL] [Abstract][Full Text] [Related]
34. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
[TBL] [Abstract][Full Text] [Related]
35. Incidence of and risk factors for severe acute kidney injury in children with heart failure treated with renin-angiotensin system inhibitors.
Terano C; Ishikura K; Miura M; Hamada R; Harada R; Sakai T; Hamasaki Y; Hataya H; Ando T; Honda M
Eur J Pediatr; 2016 May; 175(5):631-7. PubMed ID: 26687571
[TBL] [Abstract][Full Text] [Related]
36. Immune-related acute kidney injury in Australian non-small cell lung cancer patients: Real-world results.
Knox A; Cloney T; Janssen H; Solomon BJ; Alexander M; Ruderman I; John T
Lung Cancer; 2023 Oct; 184():107325. PubMed ID: 37573702
[TBL] [Abstract][Full Text] [Related]
37. Risk of acute kidney injury by initiation of non-steroidal anti-inflammatory drugs in hospitalised patients treated with diuretics and renin-angiotensin-aldosterone system inhibitors.
Bories M; Bacle A; Gilardi H; Le Corre P
Eur J Hosp Pharm; 2022 Nov; 29(6):359-361. PubMed ID: 33478983
[TBL] [Abstract][Full Text] [Related]
38. Acute kidney injury as a risk factor for mortality in oncological patients receiving checkpoint inhibitors.
García-Carro C; Bolufer M; Bury R; Castañeda Z; Muñoz E; Felip E; Lorente D; Carreras MJ; Gabaldon A; Agraz I; Serón D; Soler MJ
Nephrol Dial Transplant; 2022 Apr; 37(5):887-894. PubMed ID: 33547795
[TBL] [Abstract][Full Text] [Related]
39. Clinical Features and Outcomes of Immune Checkpoint Inhibitor-Associated AKI: A Multicenter Study.
Cortazar FB; Kibbelaar ZA; Glezerman IG; Abudayyeh A; Mamlouk O; Motwani SS; Murakami N; Herrmann SM; Manohar S; Shirali AC; Kitchlu A; Shirazian S; Assal A; Vijayan A; Renaghan AD; Ortiz-Melo DI; Rangarajan S; Malik AB; Hogan JJ; Dinh AR; Shin DS; Marrone KA; Mithani Z; Johnson DB; Hosseini A; Uprety D; Sharma S; Gupta S; Reynolds KL; Sise ME; Leaf DE
J Am Soc Nephrol; 2020 Feb; 31(2):435-446. PubMed ID: 31896554
[TBL] [Abstract][Full Text] [Related]
40. Incidence of thromboembolism in patients with melanoma on immune checkpoint inhibitor therapy and its adverse association with survival.
Sussman TA; Li H; Hobbs B; Funchain P; McCrae KR; Khorana AA
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33436486
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
